7-Oxysterols Modulate Glucocorticoid Activity in Adipocytes through Competition for 11β-Hydroxysteroid Dehydrogenase Type
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Obesity is associated with an increased risk of diabetes type 2, dyslipidemia, and atherosclerosis. These cardiovascular and metabolic abnormalities are exacerbated by excessive dietary fat, particularly cholesterol and its metabolites. High adipose tissue glucocorticoid levels, generated by the intracellular enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), are also implicated in the pathogenesis of obesity, metabolic syndrome, and atherosclerosis. 11β-HSD1 also interconverts the atherogenic oxysterols 7-ketocholesterol (7KC) and 7β-hydroxycholesterol (7β-HC). Here, we report that 11β-HSD1 catalyzes the reduction of 7KC to 7β-HC in mature 3T3-L1 and 3T3-F442A adipocytes, leading to cellular accumulation of 7β-HC. Approximately 73% of added 7KC was reduced to 7β-HC within 24 h; this conversion was prevented by selective inhibition of 11β-HSD1. Oxysterol and glucocorticoid conversion by 11β-HSD1 was competitive and occurred with a physiologically relevant IC50 range of 450 nm for 7KC inhibition of glucocorticoid metabolism. Working as an inhibitor of 11β-reductase activity, 7KC decreased the regeneration of active glucocorticoid and limited the process of differentiation of 3T3-L1 preadipocytes. 7KC and 7β-HC did not activate liver X receptor in a transactivation assay, nor did they display intrinsic activation of the glucocorticoid receptor. However, when coincubated with glucocorticoid (10 nm), 7KC repressed, and 7β-HC enhanced, glucocorticoid receptor transcriptional activity. The effect of 7-oxysterols resulted from the modulation of 11β-HSD1 reaction direction, and could be ameliorated by overexpression of hexose 6-phosphate dehydrogenase, which supplies reduced nicotinamide adenine dinucleotide phosphate to 11β-HSD1. Thus, the activity and reaction direction of adipose 11β-HSD1 is altered under conditions of oxysterol excess, and could impact upon the pathophysiology of obesity and its complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 1×
“intolerance, insulin resistance, dyslipidemia, and hypertension (7), whereas 11 -HSD1 null (11 -HSD1 / ) mice are”
BackgroundSelf-citationMorton, N. M., Paterson, J. M., Masuzaki, H., Holmes, M. C., Staels, B., Fievet, C., Walker, B. R., Flier, J. S., Mullins, J. J., & Seckl, J. R. (2004) · Diabetes · doi:10.2337/diabetes.53.4.931 · Cited by 512 · cited 5×
“11 -HSD1 / mice have a cardioprotective lipid profile (low low-density lipoprotein, high HDL) (8), and pharmacological inhibition of 11 -HSD1 activity is atheroprotective (10).”
BackgroundInfluentialSelf-citationBrown, A. J., Sun, L., Feramisco, J. D., Brown, M. S., & Goldstein, J. L. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00591-9 · Cited by 417
Brown, R. W., Chapman, K. E., Edwards, C. R., & Seckl, J. R. (1993) · Endocrinology · doi:10.1210/endo.132.6.8504762 · Cited by 271
Self-citationBujalska, I. J., Draper, N., Michailidou, Z., Tomlinson, J. W., White, P. C., Chapman, K. E., Walker, E. A., & Stewart, P. M. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01718 · Cited by 165 · cited 2×
“cells suggest that where the provision of cofactor is limiting, such as in human preadipocytes (24), accumulation of this oxysterol might attenuate glucocorticoid-mediated functions such as promotion of preadipocyte differentiation, both by substrate competition and perhaps by reaction direction reversal.”
BackgroundMethodSelf-citationIuliano, L., Micheletta, F., Natoli, S., Ginanni Corradini, S., Iappelli, M., Elisei, W., Giovannelli, L., Violi, F., & Diczfalusy, U. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(02)00467-0 · Cited by 134
Adams, M., Meijer, O. C., Wang, J., Bhargava, A., & Pearce, D. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0305 · Cited by 113 · cited 1×
“Similar results were obtained using another glucocorticoid response element-reporter construct driven by the GR-dependent phenylethanolamine N-methyltransferase gene promoter (30) (data not shown).”
ResultCai, T.-Q., Wong, B., Mundt, S. S., Thieringer, R., Wright, S. D., & Hermanowski-Vosatka, A. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00041-3 · Cited by 98
Cited by
11β-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action
Chapman, K., Holmes, M., & Seckl, J. (2013) · Physiological Reviews · doi:10.1152/physrev.00020.2012 · Cited by 887
Self-citationBrown, A. J., & Jessup, W. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.02.005 · Cited by 309
11β-Hydroxysteroid dehydrogenases and the brain: From zero to hero, a decade of progress
Wyrwoll, C. S., Holmes, M. C., & Seckl, J. R. (2011) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2010.12.001 · Cited by 244
Self-citationCooper, M. S., & Stewart, P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1412 · Cited by 183
De Fano, M., Bartolini, D., Tortoioli, C., Vermigli, C., Malara, M., Galli, F., & Murdolo, G. (2022) · doi:10.20944/preprints202204.0011.v1 · Cited by 41
Metadata
- Authors
- Wamil, M., Andrew, R., Chapman, K. E., Street, J., Morton, N. M., & Seckl, J. R.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2008-08-28
- Volume
- 149
- Issue
- 12
- Pages
- 5909-5918
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2129646574
- Cited by
- 46
- References
- 8
- FWCI
- 5.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.